Medicare
-

White House Anti-Fraud Task Force Freezes $55B as Vance Highlights Systemic Exploitation
Vice President JD Vance reported $230 billion in uncovered federal fraud and $55 billion in frozen payouts as White House enforcement expands across states.
-

Medicare Name Character Limit Causes Claim Denials for Colorado Resident
A Colorado resident faces medical bill collections after Medicare character limits caused her insurance to reject claims due to name discrepancies.
-

Advancements in Colorectal Cancer: From mRNA Vaccines to New Screening Standards
Recent breakthroughs in CRC research, including CMS coverage for non-invasive testing, long-term immunotherapy success, and the launch of preventative mRNA vaccine trials, mark a pivotal shift in managing the disease.
-

Dr. Mehmet Oz Pivots to Legal Fight Over Medicare Hemp Coverage
Dr. Mehmet Oz is spearheading a legal effort to expand Medicare coverage for hemp-based treatments, aiming to reshape federal health policies.
-

Federal Fraud Probes Face Scrutiny After Data Error
The Trump administration has admitted to a significant error in its Medicaid fraud accusations against New York, while California officials simultaneously announce a $267 million hospice fraud crackdown.
-

Medicare Faces Dual Shift: Rate Hikes and Coverage Cuts
As federal regulators finalize a 2.48% Medicare Advantage payment hike for 2027, a new law stripping coverage from thousands of legal immigrant seniors takes effect, creating a stark divide in the program’s future.
-

Trump’s Order Moves Marijuana to Schedule III: What It Means for Patients, Businesses, and Federal Law
President Trump’s executive order reclassifies marijuana as a Schedule III drug, marking a pivotal shift in U.S. drug policy. The move promises tax relief for cannabis businesses, expanded medical research, and potential Medicare coverage for CBD, but leaves recreational use…
-

CMS Announces Major Price Cuts for 15 Top Medicare Drugs Under IRA: What It Means for Patients and Pharma
The Centers for Medicare & Medicaid Services (CMS) has unveiled substantial price reductions for 15 high-cost Medicare drugs under the Inflation Reduction Act (IRA), promising significant savings for patients and taxpayers. These changes, effective from January 2027, have sparked questions…
-

Medicare Drug Price Negotiations to Continue, with Focus on Transparency
The Centers for Medicare & Medicaid Services (CMS) has announced it will proceed with Medicare drug price negotiations under the current administration, emphasizing a commitment to greater transparency in the process. This second round of negotiations will include high-profile, expensive…




